sat-1 Antibody

What is Spermidine/spermine N1-acetyltransferase 1 (SAT1) and what cellular functions does it regulate?

SAT1 (also known as SSAT1) is the key regulatory enzyme in polyamine catabolism, catalyzing the acetylation of spermidine or spermine to generate N1-acetyl derivatives. Under normal conditions, cellular SAT1 levels remain extremely low but can be rapidly induced by various stimuli including polyamines, polyamine analogs, toxic chemicals, certain drugs, and growth factors .

This enzyme plays a critical role in maintaining cellular polyamine homeostasis by enabling fine regulation of intracellular polyamine concentrations. It's also involved in polyamine transport regulation out of cells . Beyond its canonical role in polyamine metabolism, recent research has implicated SAT1 in various pathological conditions, including:

• Colorectal tumorigenesis via host-microbiota maladaptation

• Parkinson's disease pathogenesis through polyamine pathway dysregulation

• Neuropathic pain mechanisms involving ferroptosis in dorsal root ganglion

• Testicular integrity through ferroptosis regulation

For researchers investigating polyamine metabolism or these pathological conditions, understanding SAT1's enzymatic activity and regulation is essential for experimental design.

What applications are validated for SAT1 antibodies in experimental research?

SAT1 antibodies have been validated for multiple experimental applications, with varying recommended protocols:

When selecting an antibody for a specific application, researchers should consider the validation data available and the specific experimental conditions required. For example, the antibody 10708-1-AP has been validated in 23 publications for Western blot and 6 publications for IHC applications .

What species reactivity is documented for commercially available SAT1 antibodies?

Based on the search results, SAT1 antibodies show reactivity with samples from multiple species:

The species compatibility is critical when designing experiments, particularly for comparative studies across different model systems. For cross-species studies, antibodies with validated reactivity in multiple species (such as 10708-1-AP) would be advantageous.

What molecular weight should researchers expect when detecting SAT1 in Western blot experiments?

The observed molecular weight of SAT1 in Western blot applications typically ranges from 15-25 kDa , despite having a calculated molecular weight of approximately 20 kDa. This variation likely reflects:

• Post-translational modifications affecting protein mobility

• Different SAT1 isoforms

• Potential partial degradation products

When conducting Western blot analysis, researchers should include appropriate positive controls (such as HEK-293 cells, which have been identified as positive controls for SAT1 Western blots ) to confirm band specificity. The variation in observed molecular weight emphasizes the importance of validating antibody specificity through additional methods, such as knockdown/knockout controls.

How can researchers validate the specificity of SAT1 antibodies in their experimental systems?

Rigorous validation of antibody specificity is crucial for generating reliable data. For SAT1 antibodies, consider implementing these methodological approaches:

• Genetic manipulation controls:

  • KD/KO validation: Multiple publications have utilized SAT1 knockdown or knockout systems for antibody validation . This represents the gold standard for specificity confirmation.

  • Overexpression systems: Transfecting cells with SAT1 expression vectors should increase signal intensity proportionally.

• Multiple antibody validation:

  • Use antibodies targeting different epitopes of SAT1. Available options include:

    • Antibodies targeting AA 5-171 (ABIN7149863)

    • Antibodies targeting AA 1-100 (ab244505)

    • Antibodies raised against full fusion proteins (10708-1-AP)

• Peptide competition assays:

  • Pre-incubate the antibody with immunizing peptide to block specific binding sites

  • Signal elimination or significant reduction confirms specificity

• Tissue expression pattern analysis:

  • Compare staining patterns with documented SAT1 expression profiles

  • Mouse brain tissue has been validated for IHC applications

• Positive and negative controls:

  • HEK-293 cells have been identified as reliable positive controls

  • Include appropriate negative controls based on tissues with minimal SAT1 expression

This multi-faceted validation approach helps distinguish specific signals from potential cross-reactivity or non-specific binding.

What methodological considerations should guide immunohistochemical detection of SAT1?

Successful immunohistochemical detection of SAT1 requires attention to several critical parameters:

• Antigen retrieval optimization:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative approach: Citrate buffer pH 6.0

  • Systematic comparison of both methods may be necessary for specific tissue types

• Antibody dilution titration:

  • Recommended range: 1:50-1:500

  • Optimal dilution is sample-dependent and should be empirically determined

• Detection system selection:

  • Both unconjugated primary antibodies with secondary detection systems

  • Direct detection using HRP-conjugated anti-SAT1 antibodies are available

  • Biotin-conjugated variants exist for amplification strategies

• Positive control tissues:

  • Mouse brain tissue has been validated for SAT1 IHC

  • Human placenta has been successfully used with ab244505

• Signal specificity controls:

  • Include isotype controls to assess background

  • Consider peptide competition controls

  • Serial sections with primary antibody omission

For formalin-fixed, paraffin-embedded samples, appropriate deparaffinization and antigen retrieval are particularly critical for epitope accessibility. The optimization of these parameters should be systematically approached for each new tissue type under investigation.

How does SAT1 expression change under different experimental conditions, and what implications does this have for experimental design?

SAT1 expression is highly dynamic and responsive to numerous stimuli, requiring careful experimental design considerations:

• Baseline expression characteristics:

  • SAT1 typically exhibits low basal expression in most tissues and cell types

  • This low baseline necessitates sensitive detection methods for basal studies

• Induction kinetics and stimuli:

  • SAT1 can be rapidly induced by various factors including:

    • Polyamines and polyamine analogs

    • Toxic chemicals

    • Certain drugs

    • Growth factors

  • Time-course studies are essential to capture the dynamic expression window

• Pathological condition associations:

  • Downregulated in Epstein-Barr virus positive Burkitt's lymphoma cells

  • Implicated in electroacupuncture-mediated pain relief through SAT1/ALOX15 signaling

  • Involved in DEHP-induced ferroptosis in testes via p38α-lipid ROS circulation

  • Functions in p53-mediated regulation of polyamines in melanoma B16 cells

• Experimental design implications:

  • Include time-matched controls for any treatments

  • Consider examining protein and mRNA levels concurrently

  • Account for potential post-translational regulation

  • Design sampling schedules that can capture rapid expression changes

  • Use appropriate normalization controls given the dynamic expression

For researchers studying SAT1 in response to experimental manipulations, preliminary time-course studies are advisable to determine the optimal sampling time points for capturing the full dynamics of SAT1 regulation.

What are the critical methodological factors for successful Western blot detection of SAT1?

Reliable Western blot detection of SAT1 protein requires attention to several methodological factors:

• Sample preparation optimization:

  • Use extraction buffers containing protease inhibitors to prevent degradation

  • Consider phosphatase inhibitors if studying post-translational modifications

  • Optimization of protein extraction efficiency from different tissue types

• Loading control selection:

  • Choose loading controls that remain stable under your experimental conditions

  • Consider the relatively low molecular weight of SAT1 (15-25 kDa) when selecting loading controls

• Gel percentage optimization:

  • Higher percentage gels (12-15%) improve resolution in the 15-25 kDa range

  • Consider gradient gels for simultaneous detection of SAT1 and higher molecular weight proteins

• Transfer conditions:

  • Optimize transfer time and voltage for efficient transfer of small proteins

  • Consider semi-dry transfer systems for more efficient transfer of low molecular weight proteins

• Antibody dilution and incubation:

  • Recommended dilution range: 1:500-1:3000

  • Optimize primary antibody incubation time and temperature

  • Consider using signal enhancers for low abundance detection

• Detection system sensitivity:

  • Enhanced chemiluminescence (ECL) systems with varying sensitivity are available

  • Consider fluorescent Western blot systems for more quantitative analysis

  • Exposure time optimization is critical for accurate quantification

• Positive controls:

  • HEK-293 cells serve as reliable positive controls for SAT1 detection

For researchers encountering difficulty with SAT1 detection, methodical optimization of these parameters can significantly improve results, particularly when working with tissues or conditions where SAT1 expression is low.

What is Southern African Territory serotype 1 (SAT1) in the context of FMDV research?

SAT1 is one of the seven recognized serotypes of foot-and-mouth disease virus (FMDV), specifically part of the Southern African Territory group alongside SAT2 and SAT3. FMDV serotypes are classified based on their serological response to viral capsid proteins, with the complete set including O, A, C, SAT1, SAT2, SAT3, and Asia1 .

The SAT serotypes are predominantly found in Africa, with SAT1, SAT2, and SAT3 being present alongside serotypes O and A . Each serotype has been further classified into topotypes based on geographic distribution and VP1 sequence analysis.

A critical characteristic of FMDV serotypes is the lack of lasting cross-protection between them. Animals developing immunity against one serotype (through either vaccination or infection) remain susceptible to infection by other serotypes . This serotype diversity creates significant challenges for vaccination programs, which must utilize vaccines matched to circulating viral strains.

What diagnostic applications employ antibodies against FMDV SAT1?

Antibodies against FMDV SAT1 are utilized in several diagnostic applications:

• Lateral Flow Immunoassays (LFIAs):

  • Rapid field-based detection systems

  • Available in both single-serotype and multiplex formats

  • Visual detection limits of approximately 10^3.7 TCID/mL for optimized SAT1 LFIA systems

  • Critical for early detection and containment efforts

• Enzyme-Linked Immunosorbent Assays (ELISAs):

  • Liquid Phase Blocking ELISA (LPBE) for serological testing

  • Single-chain antibody fragments (scFvs) have shown potential as detecting reagents in LPBE systems

  • Used for quantitative analysis in laboratory settings

• Serum Neutralization Tests (SNTs):

  • Gold standard for serotyping FMDV antibody responses

  • Used to assess vaccine efficacy

  • Employed in determining cross-reactivity between FMDV strains

• Multiplex Detection Systems:

  • Simultaneous detection of multiple FMDV serotypes

  • Typical configuration includes anti-SAT1, anti-SAT2, pan-FMDV, and control antibodies

  • Allows comprehensive serotype identification in a single test

These diagnostic applications are critical for FMDV surveillance, outbreak control, and vaccine matching studies.

What are the key antigenic sites on FMDV SAT1 recognized by antibodies?

Research has identified four independent antigenic determinants on FMDV SAT1:

• Two distinct sites located within the βG–βH loop of VP1

• Two simultaneous residues: one in VP3 (position 135 or 71 or 76) and one in VP1 (position 179 or 181)

• A conformation-dependent site created by the interaction between VP1 position 181 and VP2 position 72

• A site centered on VP1 position 111

The majority of FMDV-neutralizing antibodies target conformational epitopes found on the β-barrel connecting loops, with particular importance placed on the highly mobile βG–βH loop in VP1 . This loop is a primary target for neutralizing antibodies across FMDV serotypes.

Understanding these antigenic sites is crucial for:

• Developing effective diagnostics with appropriate epitope targeting

• Designing vaccines that stimulate protective immunity

• Interpreting antigenic differences between circulating strains

• Predicting potential for cross-protection

Knowledge of these specific antigenic determinants, especially those functioning as protective epitopes, significantly enhances our understanding of virus neutralization in vivo.

How are antibodies against FMDV SAT1 generated for research and diagnostic applications?

Several approaches are employed to generate antibodies against FMDV SAT1:

• Traditional monoclonal antibody production:

  • Immunization of laboratory animals (typically mice) with inactivated SAT1 virus or recombinant proteins

  • Hybridoma generation through fusion of B cells with myeloma cells

  • Screening and selection based on specificity and affinity for SAT1 epitopes

• Recombinant antibody technologies:

  • Phage display libraries: The Nkuku® library has been successfully used for biopanning against SAT1 virus

  • Single-chain variable fragments (scFvs): Biopanning yielded unique scFv binders specific to SAT1

  • These technologies allow antibody generation without animal immunization

• Host-relevant antibody production:

  • Bovine-derived antibodies have shown value for identifying protective and latent determinants on FMDV capsids

  • Particularly relevant as bovines are natural hosts for FMDV

  • May identify epitopes missed by antibodies from non-host species

• Pan-serotype antibodies:

  • Some approaches focus on generating antibodies recognizing epitopes conserved across FMDV serotypes

  • The antibody designated 1F10 has been used as a PAN-FMDV detecting antibody in multiplex systems

Each approach offers different advantages for specific research and diagnostic applications, with selection dependent on the intended use and resources available.

What experimental design strategies optimize multiplex lateral flow immunoassays (LFIAs) for FMDV SAT1 detection?

Developing effective multiplex LFIAs for SAT1 detection requires systematic optimization of multiple variables. Research has identified several critical factors:

• Test line positioning optimization:

  • The positioning of capture antibodies along the LFIA strip significantly impacts sensitivity

  • This has been identified as the most influential variable for improving detectability

  • Increasing distance between the line and sample application point decreases detectability

• Antibody selection and concentration:

  • Specific monoclonal antibodies:

    • Anti-SAT1 (#HD7) at 1.0mg/mL for the T2 line

    • Anti-SAT2 (#2H6) at 1.5mg/mL for the T1 line

    • PAN-FMDV (#1F10) at 1.0mg/mL for the T3 line

    • Control line: rabbit anti-mouse (7023) at 0.3mg/mL

• Design of Experiments (DoE) approach:

  • Instead of trial-and-error optimization, statistical experimental design provides more efficient results

  • 13-experiment optimal design maximizes efficiency (measured as log Normalized Determinant)

  • 9-experiment "sub-optimal" design provides the minimum number of experiments for consistent evaluation

• Signal reporter optimization:

  • Gold nanoparticle-antibody conjugates (mAb_AuNPs) serve as signal reporters

  • Three critical factors influence performance:

    • The order in which different mAb_AuNPs encounter the antigen

    • The concentration of mAb_AuNPs (higher numbers can saturate antigen epitopes)

    • The density of antibodies on individual AuNPs (affecting probe affinity)

• Gold conjugate characterization:

  • Successful conjugation produces a red-shift in localized surface plasmon resonance (LSPR)

  • #HD7_AuNPs showed a 6 nm red-shift regardless of mAb amount

  • #2H6_AuNPs showed 6-7 nm red-shifts depending on mAb concentration

Through systematic optimization of these parameters, researchers have achieved visual detection limits of 10^3.7 TCID/mL for SAT1 , representing a two-fold sensitivity increase over previous designs.

How can researchers differentiate between FMDV serotypes using antibody-based methods?

Effective differentiation between FMDV serotypes through antibody-based methods requires several methodological considerations:

• Serotype-specific monoclonal antibodies:

  • Select antibodies validated for specificity against a particular serotype

  • For SAT1, antibodies targeting unique epitopes within the βG–βH loop of VP1 or the conformation-dependent site within VP1 position 181 and VP2 position 72

  • Validate specificity against multiple isolates within the target serotype

• Multiplex detection platforms:

  • Lateral flow designs with multiple test lines

    • Typical configuration includes separate lines for SAT1, SAT2, and a pan-FMDV antibody

    • Optimize the order of test lines based on antibody characteristics

  • Multiplex ELISA systems

    • Utilize different detection chemistries or spatially separated capture antibodies

• Serum neutralization testing methodologies:

  • Gold standard for serotyping

  • Protocol follows OIE manual guidelines using reference viruses:

    • SAT1/SW/3/49 (of South West Africa) for SAT1

    • Appropriate reference strains for other serotypes

  • Requires facilities capable of handling live FMDV

• Single-chain antibody fragments (scFvs):

  • Novel approach using phage display technology

  • Biopanning has yielded serotype-specific scFvs

  • SAT1-specific scFv showed reactivity with a panel of SAT1 viruses in liquid phase blocking ELISA

• Cross-reactivity assessment:

  • Comprehensive validation against multiple serotypes

  • Testing against phylogenetically diverse isolates within each serotype

  • Determining minimal cross-reactivity thresholds acceptable for diagnostic purposes

These methods allow researchers to accurately differentiate between FMDV serotypes, which is essential for epidemiological studies, vaccine matching, and outbreak control measures.

What validation methods should be implemented when developing new antibody-based diagnostics for FMDV SAT1?

Rigorous validation is essential when developing antibody-based diagnostics for FMDV SAT1. A comprehensive validation protocol should include:

• Analytical sensitivity assessment:

  • Establish limit of detection (LOD) using quantified viral stocks

  • Determine analytical sensitivity in TCID/mL (tissue culture infective dose)

  • Optimized LFIAs have achieved visual detection limits of 10^3.7 TCID/mL for SAT1

• Analytical specificity evaluation:

  • Cross-reactivity testing against:

    • Other FMDV serotypes (O, A, C, SAT2, SAT3, Asia1)

    • Related vesicular disease viruses

    • Common contaminants in sample matrices

• Intra-serotype variation testing:

  • Evaluate performance across multiple SAT1 isolates

  • Include phylogenetically diverse strains

  • The SAT1-specific scFv has shown varied ELISA absorbance signals across different SAT1 viruses

• Sample matrix validation:

  • Test performance in relevant sample types (epithelial suspensions, cell culture supernatants)

  • Evaluate potential matrix interference effects

  • Establish sample preparation protocols to minimize interference

• Comparative method assessment:

  • Compare with reference methods (virus isolation, RT-PCR)

  • Determine concordance with serum neutralization test results

  • Calculate diagnostic sensitivity and specificity

• Reproducibility and repeatability studies:

  • Within-lab reproducibility across different operators and days

  • Between-lab reproducibility if possible

  • Lot-to-lot consistency for manufactured reagents

• Field validation:

  • Performance evaluation under real-world conditions

  • Testing in endemic regions with naturally infected animals

  • Assessment of test suitability for field use

• Reference panel testing:

  • Validation using well-characterized reference panels

  • Include samples with varied viral loads

  • Include samples from different geographical regions

This comprehensive validation approach ensures that new diagnostics will perform reliably under various conditions and with diverse SAT1 strains, ultimately supporting effective disease surveillance and control.

How do recombinant antibody technologies like scFv compare to traditional monoclonal antibodies for FMDV SAT1 detection?

Recombinant antibody technologies, particularly single-chain variable fragments (scFvs), offer several distinct advantages and limitations compared to traditional monoclonal antibodies for FMDV SAT1 detection:

• Performance characteristics:

  • Specificity: SAT1-specific scFvs have demonstrated selective reactivity with SAT1 viruses

  • Binding properties: Different scFvs exhibit varying ELISA absorbance signals across SAT1 viral isolates

  • Structural stability: SAT1scFv1 maintains its paratope structure when immobilized on polystyrene plates

• Production advantages:

  • Expression systems: scFvs can be produced in bacterial systems rather than requiring hybridoma culture

  • Scalability: Potentially easier scale-up for production

  • Reduced biological safety requirements: No need for viral culture during antibody production

  • Phage display selection allows rapid identification of binders from large libraries

• Structural benefits:

  • Smaller size: Approximately 25-30 kDa compared to 150 kDa for full IgG

  • Potential access to epitopes inaccessible to larger antibodies

  • More consistent performance due to recombinant nature

• Novel applications:

  • Both capturing and detecting reagents: scFvs have shown potential in both roles for diagnostic ELISA development

  • Epitope mapping studies: Used in virus neutralization assays to identify antigenic determinants

  • Fusion proteins: Can be readily fused to detection tags or therapeutic moieties

• Limitations:

  • Monovalency: Single binding site compared to bivalent binding of complete antibodies

  • Potential reduced affinity compared to full-length antibodies

  • Possible stability challenges in certain environments

The unique properties of scFvs make them valuable tools for FMDV research, particularly for developing improved diagnostic platforms and for epitope identification studies. Their successful application for SAT1 detection demonstrates their viability as alternatives to traditional monoclonal antibodies in this field.

What strategies can improve the detection sensitivity of antibody-based assays for FMDV SAT1?

Enhancing detection sensitivity for FMDV SAT1 requires optimizing multiple aspects of antibody-based assays:

• Antibody selection and engineering:

  • Affinity maturation: Select or engineer antibodies with higher binding affinity

  • Epitope targeting: Focus on accessible and abundant epitopes on the virion

  • Paratope preservation: Ensure antibody immobilization methods maintain binding site structure

    • SAT1scFv1 has demonstrated preserved paratope structure when immobilized

• Assay format optimization:

  • Test line positioning: Identified as the most influential variable for sensitivity in lateral flow assays

  • Capture antibody concentration: Typical effective concentration of 1.0-1.5 mg/mL

  • Sample flow rate control: Optimize membrane selection and buffer composition

• Signal enhancement strategies:

  • Gold nanoparticle optimization:

    • Size selection affects visual signal intensity

    • Antibody coating density influences binding avidity

    • Red-shift in LSPR (6-7 nm) indicates successful conjugation

  • Alternative detection systems:

    • Fluorescent labels for instrumental readout

    • Enzymatic amplification for colorimetric assays

    • Quantum dots or other advanced nanomaterials

• Hook effect mitigation:

  • Optimize antibody-to-antigen ratios

  • Design assays with broad dynamic ranges

  • Consider sample dilution protocols for highly positive samples

• Statistical design of experiments:

  • Implement 13-optimal DoE approach for systematic optimization

  • Evaluate key variables simultaneously rather than sequentially

  • This approach has yielded a two-fold sensitivity increase, reaching visual detection limits of 10^3.7 TCID/mL for SAT1

• Sample preparation refinement:

  • Optimize virus extraction protocols from clinical samples

  • Implement pre-analytical concentration steps

  • Remove potential interfering substances

• Instrument-based detection:

  • Reader systems for quantitative assessment of weak positive signals

  • Image analysis algorithms to detect signals below visual threshold

  • Time-resolved measurements to capture optimal signal window

By systematically implementing these strategies, researchers have successfully improved SAT1 detection sensitivity, which is crucial for early diagnosis and effective control of FMDV outbreaks.